Free Trial
→ Strange crypto pattern discovered by 40-person research team (From Crypto Swap Profits) (Ad)tc pixel Free ALPMY Stock Alerts

Astellas Pharma (ALPMY) Stock Forecast & Price Target

Astellas Pharma logo
$11.56 +0.33 (+2.94%)
As of 09/18/2025 03:59 PM Eastern
Compare

Astellas Pharma - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Buy
Based on 2 Analyst Ratings
Sell
0
Hold
1
Buy
1

Based on 2 Wall Street analysts who have issued ratings for Astellas Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 2 analysts, 1 has given a hold rating, and 1 has given a strong buy rating for ALPMY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ALPMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Astellas Pharma and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALPMY Analyst Ratings Over Time

TypeCurrent Forecast
9/19/24 to 9/19/25		1 Month Ago
8/20/24 to 8/20/25		3 Months Ago
6/21/24 to 6/21/25		1 Year Ago
9/20/23 to 9/19/24
Strong Buy
1 Strong Buy rating(s)
 N/A N/A N/A
Buy
0 Buy rating(s)
 N/A N/A N/A
Hold
1 Hold rating(s)
 N/A N/A N/A
Sell
0 Sell rating(s)
 N/A N/A N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingBuyN/AN/AN/A

ALPMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALPMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Astellas Pharma Stock vs. The Competition

TypeAstellas PharmaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.78
2.53
Consensus RatingBuyModerate BuyModerate Buy
Predicted UpsideN/A13,473.43% Upside10.79% Upside
News Sentiment Rating
Positive News

See Recent ALPMY News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
9/9/2025Zacks Research
0 of 5 stars		 UpgradeHold ➝ Strong-Buy
9/2/2025Sanford C. Bernstein
4 of 5 stars		 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:47 AM ET.


Should I Buy Astellas Pharma Stock? ALPMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 12, 2025. Please send any questions or comments about these Astellas Pharma pros and cons to contact@marketbeat.com.

Astellas Pharma
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Astellas Pharma Inc.:

  • Astellas Pharma Inc. has a strong portfolio of innovative treatments, including XTANDI for prostate cancer and PADCEV for metastatic urothelial cancer, which are critical in addressing significant medical needs.
  • The current stock price is around $9.77, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • The company is actively engaged in research collaborations, such as with Vivtex Corporation, which could lead to the development of novel therapies and enhance its product pipeline.
  • Astellas Pharma Inc. has established partnerships, including one with Roche Diabetes Care Japan, aimed at developing integrated diabetes management solutions, potentially expanding its market reach.
  • With a focus on chronic conditions, including anemia associated with chronic kidney disease, Astellas Pharma Inc. is positioned to benefit from the growing demand for long-term treatment options.

Astellas Pharma
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Astellas Pharma Inc. for these reasons:

  • The company has a relatively low short percentage of float, indicating limited investor confidence, which could affect stock performance.
  • Recent data shows a month-to-month decrease in shares shorted, suggesting potential volatility in investor sentiment.
  • Astellas Pharma Inc. has no institutional ownership, which may indicate a lack of confidence from larger investors and could impact stock stability.
  • The average daily trading volume is around 625,500 shares, which may suggest lower liquidity compared to larger pharmaceutical companies, potentially leading to higher volatility.
  • With no outstanding shares reported, there may be concerns regarding the company's market presence and ability to attract new investments.

ALPMY Forecast - Frequently Asked Questions

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There is currently 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ALPMY shares.

According to analysts, Astellas Pharma's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Astellas Pharma's stock had 1 upgrade and 1 downgrade by analysts.

Astellas Pharma has been rated by research analysts at Sanford C. Bernstein, and Zacks Research in the past 90 days.

Analysts like Astellas Pharma more than other "medical" companies. The consensus rating for Astellas Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ALPMY compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (OTCMKTS:ALPMY) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...
The Oxford Club | Sponsoredtc pixel
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...
Investors Alley | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Strange crypto pattern discovered by 40-person research team
Something unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...
Crypto Swap Profits | Sponsoredtc pixel
IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...
American Alternative | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel